Feds Continue to Fund Moderna Including $144m Injection into 2/3 KidCOVE Study (11yr to 6 months) Despite Record Revenues & Profits & $8b cash reserves

Feds Continue to Fund Moderna Including $144m Injection into 2/3 KidCOVE Study (11yr to 6 months) Despite Record Revenues & Profits & $8b cash reserves

Moderna, an innovative biotech leading the life-sciences-driven mRNA-based revolution, has proven just as adept at securing public (taxpayer) financing as developing breakthrough mRNA-based vaccines. Times have never been better for the Cambridge, MA-based company, one that was operating at well over a quarter billion dollar annual loss as the company transitioned from 2018 to 2019. TrialSite profiled this company’s IPO at $23 per share…the price is now $219.94 and a $88 billion market capitalization. With Q1 generating $1.73 billion in vaccine-related revenue, the innovative mRNA-focused biotech achieved profitability for the first time. Their annual forecast hits a staggering $19.2 billion thanks to the confluence of pandemic, quality product, and government subsidy. But they’ve turned out to become a business innovator, one originally profiled by the TrialSite as “Developing the Software of Life.”  Yet a growing vaccine hesitancy does raise questions about not only public sentiment but also actual safety indicators. A recent FDA warning combined with other reports of safety anomalies suggest broader investigation. And debates about vaccinating young children grow, as prominent ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee